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Abstract
Background: Palmitoylation, the addition of palmitate to proteins by palmitoyl acyltransferases (PATs), is an
important regulator of synaptic protein localization and function. Many palmitoylated proteins and PATs have been
implicated in neuropsychiatric diseases, including Huntington disease, schizophrenia, amyotrophic lateral sclerosis,
Alzheimer disease, and X-linked intellectual disability. HIP14/DHHC17 is the most conserved PAT that palmitoylates
many synaptic proteins. Hip14 hypomorphic mice have behavioral and synaptic deficits. However, the phenotype is
developmental; thus, a model of post-developmental loss of Hip14 was generated to examine the role of HIP14 in
synaptic function in the adult.
Results: Ten weeks after Hip14 deletion (iHip14Δ/Δ), mice die suddenly from rapidly progressive paralysis. Prior to
death the mice exhibit motor deficits, increased escape response during tests of anxiety, anhedonia, a symptom
indicative of depressive-like behavior, and striatal synaptic deficits, including reduced probability of transmitter
release and increased amplitude but decreased frequency of spontaneous post-synaptic currents. The mice also
have increased brain weight due to microgliosis and astrogliosis in the cortex.
Conclusions: Behavioral changes and electrophysiological measures suggest striatal dysfunction in iHip14Δ/Δ mice,
and increased cortical volume due to astrogliosis and microgliosis suggests a novel role for HIP14 in glia. These
data suggest that HIP14 is essential for maintenance of life and neuronal integrity in the adult mouse.
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Background
In recent years palmitoylation has emerged as an im-
portant regulator of protein localization and function,
particularly in neurons [1, 2]. Palmitoylation is the re-
versible addition of long chain fatty acids, typically
palmitate, to proteins at cysteine residues [3, 4]. It is
mediated by DHHC-domain containing palmitoyl acyl-
transferases (PATs) that palmitoylate proteins at cysteine
residues via a thioester bond [5, 6]. Many PATs have been
implicated in diseases of the nervous system, including
Huntington disease (HD), an autosomal dominant fatal
neurodegenerative disease; schizophrenia; amyotrophic
lateral sclerosis; Alzheimer disease; and X-linked intellec-
tual disability [1, 2].
Palmitoylation is the only reversible lipid modifica-
tion, and this reversibility is analogous to phosphoryl-
ation, where enzyme-mediated addition and removal of
palmitate allows for rapid cycling of palmitate on some
proteins, providing an additional level of regulation of
localization and function [7]. Indeed, in neurons, palmi-
toylation has been shown to regulate localization of
many synaptic proteins. For example, palmitoylation of
post-synaptic density protein 95 (PSD95) is required for
its synaptic localization, and its palmitoylation undergoes
cycles of de/repalmitoylation that regulate PSD95 nanoclus-
ters within the synapse [8]. Palmitoylation also regulates
the synaptic insertion/removal of α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor (AMPAR)
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subunits GluA1 and GluA2, and of N-methyl-D-aspartate
receptor (NMDAR) subunits GluN2A and GluN2B [9, 10].
Huntingtin interacting protein 14 (HIP14 or ZDHHC17)
is the most highly conserved of the 23 human PATs. It
palmitoylates many synaptic proteins, including cyst-
eine string protein (CSP), GluA1, GluA2, PSD95,
synaptosomal-associated protein 25 (SNAP25), synap-
totagmin 1 (SYT1), the large conductance calcium- and
voltage-activated potassium BK channel (KCNMA1)
STREX isoform, and the HD disease-causing protein
huntingtin (HTT) [2]. It has recently become more appar-
ent that HIP14 is an important regulator of synaptic func-
tion. Indeed, Hip14 knockdown reduces PSD95 clustering
in neurons [6] and in Drosophila melanogaster HIP14 is
required for CSP targeting to synaptic vesicles and, in
turn, pre-synaptic exocytosis [11]. Interestingly, in an HD
mouse model HIP14 is less active [12, 13] and the consti-
tutive Hip14-deficient mouse (Hip14gt/gt) has behavioral,
neuropathological, and synaptic dysfunction reminiscent
of HD [12, 14, 15].
The Hip14gt/gt mouse is a hypomorph expressing ~10%
of endogenous HIP14 protein [16, 17] and the phenotype
is developmental, as neurodegeneration occurs during late
embryogenesis. Thus, we sought to determine the conse-
quences of complete loss of Hip14 in the adult animal and
its effect on synaptic deficits and neuronal degeneration.
An inducible Hip14-deficient mouse model was generated,
and Hip14 deletion was induced in the young adult
mouse.
Results
Generation of post-development Hip14-deficient mice
Hip14 “conditional knockout” (Hip14F/F) mice (Fig. 1a–d)
were crossed to ubiquitously expressed tamoxifen
(TM)-inducible Cre recombinase (Cre-ERT2)-expressing
transgenic mice [18]. Hip14 deletion was induced in
Hip14F/F;Cre + mice at 6 weeks of age by TM treatment
(iHip14Δ/Δ herein) to allow mice a month to recover
from TM toxicity prior to any behavior testing per-
formed at 3 months of age [19].
Hip14mRNA and protein levels were assessed at 10 days
after the last injection and 6 weeks post-induction to as-
sess deletion efficiency compared to Hip14F/F;Cre– TM
control mice (iHip14F/F herein). Hip14mRNA and protein
expression was decreased by >90% 10 days post-TM treat-
ment in all brain regions and peripheral tissues tested
(Fig. 1e and f). Greater than 95% loss of HIP14 protein
was observed in the whole brain at 6 weeks post-TM
treatment (Fig. 1f). These data indicate that deletion of
Hip14 in iHip14Δ/Δ mice is >90% effective.
Low body weight and hyperactivity in iHip14Δ/Δ mice
To assess overall health, iHip14Δ/Δ mice were weighed at
3 months of age, approximately 7 weeks post-induction.
Both female and male iHip14Δ/Δ mice were approximately
10% smaller than wild-type (WT) vehicle (VEH)-treated
and iHip14F/F control mice (Fig. 2a and b). To assess
global nervous system and motor function, spontaneous
activity was assessed during the dark phase. iHip14Δ/Δ
mice were hyperactive during exploration of a novel envir-
onment (increased distance traveled, Fig. 2c, and ambula-
tory time, d).
Motor coordination and sensorimotor gating deficits in
iHip14Δ/Δ mice
To determine if loss of HIP14 in the adult mouse results
in neurological dysfunction, motor function was assessed.
Motor coordination of iHip14Δ/Δ mice was tested on
rotarod and climbing tests [20]. iHip14Δ/Δ mice had motor
coordination deficits on the rotarod compared to control
WT VEH and iHip14F/F mice (Fig. 3a). As the rotarod per-
formance is a trained test where mice learn to stay on the
rotarod, it is less sensitive to motor dysfunction than the
spontaneous test of motor coordination: climbing [21, 22].
There was also a dramatic reduction in the number of
climbing events in these mice (Fig. 3b) but no change in
the number of rearing events, indicative of motivation to
explore the apparatus (Fig. 3c). Taken together, these data
indicate motor dysfunction.
Schizophrenia and other neurological disorders were
recently shown to be enriched for palmitoylated proteins
[1]. Pre-pulse inhibition (PPI) is a test of sensorimotor
gating, partly mediated by the striatum [20, 23]. PPI defi-
cits are associated with schizophrenia and other psychi-
atric disorders as well as HD [24]. When a quieter tone
(the pre-pulse) is played prior to a loud stimulus (the
startle pulse), mice with intact sensorimotor gating will
startle less than they would to the loud startle stimulus
alone [25]. iHip14Δ/Δ mice showed impaired pre-pulse
inhibition at all pre-pulse levels that was significant at 2,
4, and 9 dB above background with a trend at 16 dB
compared to control mice (Fig. 3d), indicating impaired
sensorimotor gating and potential striatal dysfunction.
Increased escape response and anhedonia in iHip14Δ/Δ mice
As it is becoming increasingly evident that palmitoylation
is important in neuropsychiatric disorders [1, 2], the im-
pact of loss of HIP14 on psychiatric phenotypes such as
depression and anxiety was assessed [21, 26]. iHip14Δ/Δ
mice were tested in the Porsolt forced swim test for de-
pression [26–28]. Interestingly, iHip14Δ/Δ mice spent dra-
matically less time immobile during forced swimming
than controls (Fig. 4a). During behavior testing iHip14Δ/Δ
mice were observed to be very reactive to the experi-
menter and testing conditions, having explosive responses
to both. Thus, rather than truly reflecting an anti-
depressive effect, these data in the forced swim test are
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consistent with the hyperactivity and reactivity to testing
observed in these mice.
Anxiety-like behavior was assessed in the open field ex-
ploration test, a well-established test of anxiety-like behav-
iors in rodents [21, 29]. iHip14Δ/Δ mice explored the
brightly lit open field to the same extent as control mice,
as measured by distance traveled (Fig. 4b), but spent less
time in the center of the field (Fig. 4c), suggesting an in-
crease in anxiety-like behaviors in these mice.
To confirm anxiety in iHip14Δ/Δ mice, the mice were
tested using the elevated plus maze (EPM) test for anxiety
[30, 31]. Surprisingly, the iHip14Δ/Δ mice spent more time
in the open arms of the EPM than the control WT VEH
or iHip14F/F mice (Fig. 4d), suggesting decreased anxiety,
Fig. 1 Generation of Hip14 conditional knockout mice. The targeting vector that was used is shown in (a). It was generated using PCR cloning of
the 5′ and 3′ homology arms (5.5 and 3.2 kbp, respectively) and the deletion region (conditional knockout region [cKO]) with the indicated
restriction enzyme sites added by PCR and used for cloning into the targeting vector, such that loxP sites are oriented in the same direction up
and downstream of the cKO region. The deletion region, in gray, includes exon 2 and upstream and downstream intronic sequences to a total of
1.1 kbp. The targeting vector also includes a positive neomycin (Neo) selection cassette flanked by flippase recognition target (frt) sites and a
negative diphtheria toxin A (DTA) selection cassette outside of the homology arms. The wild-type (WT) allele is shown in (b) with the 5′ and 3′
homology arms and the cKO region indicated. The recombined allele (Hip14F) is shown in (c). The neo cassette was removed during embryonic
cell culture after targeting by electroporation with Flp recombinase and negative selection with G418. The knockout allele following expression of
Cre recombinase is shown in (d) where recombination between the loxP sites occurs by the action of Cre leading to deletion of the cKO region,
including exon 2. This deletion results in a frameshift mutation and multiple premature stop codons. The expression of Hip14 mRNA in the striatum,
hippocampus, cortex, cerebellum, spleen, liver, kidney, and heart in iHip14Δ/Δ mice and in iHip14F/F control mice relative to β-actin is shown
in (e) (N = 3). There was a 90% or greater decrease in Hip14 mRNA in iHip14Δ/Δ mice compared to control mice. f HIP14 protein expression
in the striatum, hippocampus, cerebellum, and cortex from iHip14Δ/Δ and iHip14F/F mice, where the tissues were collected 10 days post-TM
treatment, is shown. Also shown is whole brain collected 6 weeks post-TM treatment from iHip14Δ/Δ and iHip14F/F mice. Whole cell lysate
was run on western blot and probed with anti-HIP14 and anti-β-tubulin antibodies. The HIP14 immunoblot is the top panel in each set of
images; the β-tubulin is in the bottom panel. The amount of HIP14 protein expressed is quantified in the graph relative to β-tubulin expression
(N = 2–10). A 90% or greater decrease in HIP14 was observed in iHip14Δ/Δ mice. Data were analyzed using Student’s t test
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opposite to the findings from the open field testing. The
iHip14Δ/Δ mice did not explore the EPM as much as the
control mice (Fig. 4e), likely because they spent more time
dipping their head off the edge of the open arms of the
maze (Fig. 4f), again suggesting decreased anxiety. These
data suggest an anxiolytic phenotype rather than the
anxiogenic phenotype suggested by the open field explor-
ation test. Alternatively, the iHip14Δ/Δ mice may be trying
to escape the testing apparatus; i.e., they spend more time
exploring the edges of the open field box trying to find a
way out, and in the EPM they dip their heads off the open
arms trying to escape the maze. This interpretation would
also be consistent with their reactivity to handling and
testing and reduced time spent immobile in the forced
swim test.
To separate anxiety-like behavior from increased escape
response, a modified light-dark box test was designed that
completely removed any possibility of escape, where one
side was dark and the other side was brightly lit, and both
sides were completely enclosed. The iHip14Δ/Δ mice spent
the same amount of time in the light box as the control
mice (Fig. 4g). These data suggest iHip14Δ/Δ mice are not
anxious per se but have an increased escape response.
To delineate escape response from depressive-like be-
havior, the iHip14Δ/Δ mice were tested using the sucrose
preference test for anhedonia-like behavior (the inability
to experience pleasure), as anhedonia is a major symptom
of depression [26, 32]. The sucrose preference test is
performed in the home cage with no experimenter
present, thus eliminating the confound of increased escape
response. The iHip14Δ/Δ mice consumed the same
amount of fluid (Fig. 4g) but had decreased preference for
sucrose compared to the control mice (Fig. 4h), indicating
anhedonia and suggesting a depressive-like phenotype.
Increased forebrain weight, increased cortical volume,
and decreased corpus callosum volume in iHip14Δ/Δ mice
To determine the effect of loss of HIP14 in the adult
mouse on brain morphology and neurodegeneration,
neuropathological assessments were performed. Increased
brain weight was observed in iHip14Δ/Δ mice (Fig. 5a).
This increase was restricted to the forebrain (Fig. 5b), as
there was no change in cerebellar weight compared to
Fig. 3 Motor coordination and sensorimotor gating deficits in 3-month
old iHip14Δ/Δ mice. Over three consecutive days, 3-month-old mice were
trained on a fixed-speed rotarod and tested on an accelerating rotarod
on the fourth day (a). The number of falls (left) and the latency to the
first fall (right) were recorded. iHip14Δ/Δ mice fell off the rotarod more
(two-way ANOVA: genotype p = 0.0053, p < 0.0001; interaction
p= 0.9071; N= 14–16) and sooner (two-way ANOVA: genotype p=
0.0009, training day p< 0.0001, interaction p = 0.4581; N= 14–16) both
during training and during testing. Mice were allowed to freely explore
and climb a wire mesh container. iHip14Δ/Δ mice climbed fewer times
(b; ANOVA: p = 0.001; N = 13–18) but did not rear less (c; ANOVA: p =
0.65; N= 13–18) compared to control mice. Pre-pulse inhibition (PPI)
was measured as the percentage of decrease in the magnitude
(velocity) of startle with a pre-pulse compared to the magnitude of
startle without a pre-pulse. iHip14Δ/Δ mice had a PPI deficit compared to
controls (d; repeated measures ANOVA: genotype p < 0.0001, pre-pulse
p< 0.0001; N= 15–18)
Fig. 2 Decreased body weight and hyperactivity in 3-month old
iHip14Δ/Δ mice. A ~10% decrease in body weight of female (a;
analysis of variance, ANOVA: p < 0.0001) and male (b; ANOVA:
p < 0.0001) iHip14Δ/Δ mice compared to WT VEH and iHip14F/F mice
was observed (N = 16–24). Spontaneous activity was assessed by
infrared beam breaks during a 30-min exploration of a 27 × 27 ×
20.3 cm box at 3 months of age. Total distance traveled (c) and
ambulatory time as assessed by consecutive beam breaks (d) were
assessed. On both measures the iHip14Δ/Δ mice were hyperactive
compared to controls (distance traveled ANOVA: p = 0.0005;
ambulatory time ANOVA: p=<0.0001; ambulatory episodes ANOVA
p= 0.0001; N= 13–18)
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WT VEH control mice (Fig. 5c). Also, unexpectedly,
there was no change in striatal volume in the iHip14Δ/Δ
mice compared to controls (Fig. 5d), but there was an
increase in cortical volume (Fig. 5e) and a decreased
corpus callosum volume, indicating loss of white matter
(Fig. 5f ) potentially due to axonal degeneration or loss
of myelination.
To understand what factors may account for the ob-
served increase in cortical volume, astrocytes and
microglia were assessed by glial fibrillary acidic protein
(GFAP) and ionized calcium-binding adapter molecule
1 (IBA1) staining intensity, respectively. There was a
dramatic increase in both GFAP (Fig. 5g and i) and
IBA1 (Fig. 5h and j) staining intensity in the cortex of
iHip14Δ/Δ mice compared to controls, indicating signifi-
cant astrogliosis and microgliosis, respectively.
Impaired synaptic transmission in the striatum of
iHip14Δ/Δ mice
Since palmitoylation has been implicated in localization
of synaptic proteins and in synaptic signaling and HIP14
was previously shown to be important for striatal physi-
ology and striatal processing during motor behaviors
[14, 15], the synaptic properties of medium-sized spiny
neurons (MSNs) in the striatum of iHip14Δ/Δ mice were
examined [14, 33–35] by making current- and voltage-
clamp recordings in the dorsal striatum. We observed
no significant effect of loss of Hip14 on either MSN rest-
ing membrane potential or rheobase (Fig. 6a–c): the
amount of current injection required to initiate action
potential firing. Membrane capacitance, an indirect
measure of cell-surface area, was also similar between
groups (Fig. 6d). Thus, MSN membrane potential, excit-
ability, and cell size appear to be unaltered by loss of
Hip14 in adulthood.
To assay excitatory synaptic function, AMPAR-mediated
spontaneous excitatory post-synaptic currents (sEPSCs)
were recorded from MSNs held at –70 mV in the presence
of picrotoxin, a γ-aminobutyric acid A (GABAA) receptor
antagonist. There was a significant decrease in the fre-
quency and a significant increase in the amplitude of
sEPSCs recorded from iHip14Δ/Δ MSNs (Fig. 6e and f)
compared to controls. These data demonstrate synaptic
dysfunction in iHip14Δ/Δ mice and suggest a reduction in
the number of excitatory synapses and/or a reduction in
transmitter release probability with additional AMPARs at
the synapses or more glutamate released per synaptic
vesicle.
To assess transmitter release probability from cortical
afferents onto MSNs in the striatum, a stimulating elec-
trode was placed 200–250 μm dorsal to the recorded
cell, various inter-pulse intervals were applied, and the
paired pulse ratio (PPR) was calculated. MSNs from
iHip14Δ/Δ mice had increased PPRs compared to MSNs
from control mice (Fig. 6g and h). These data are indi-
cative of a lower probability of transmitter release and
are consistent with the reduction in sEPSC frequency,
further suggesting synaptic dysfunction.
Reduced survival due to rapidly progressing paralysis in
iHip14Δ/Δ mice
As mice were being aged for longitudinal behavior studies,
a dramatic decrease in survival of iHip14Δ/Δ mice, begin-
ning at about 16 weeks of age or 10 weeks post-Hip14 de-
letion, was observed (Fig. 7a). Typically, all mice appeared
healthy prior to sudden death. Six mice were found with
hind limb paralysis prior to being euthanized for other
Fig. 4 Three-month-old iHip14Δ/Δ mice have increased escape
response and display anhedonic-like behavior. iHip14Δ/Δ mice spent
significantly less time immobile in the forced swim test (a; ANOVA:
p = 0.0272; N = 15–19). Mice were placed in an open field under
bright lighting. iHip14Δ/Δ mice explored the field to the same extent
as the control mice (b; ANOVA p = 0.0844; N = 24–25) but spent less
time in the center (c; ANOVA: p < 0.0001; N = 24–25). iHip14Δ/Δ mice
spent more time in the open arms of the elevated plus maze (d;
ANOVA: p < 0.0001; N = 25–34; EPM), explored the maze less (e; ANOVA:
p = 0.0007; N = 25–34), and dipped their heads off the edge of the
open arms more (f; ANOVA: p = 0.0001; N = 25–34) than controls. Mice
were placed in an enclosed box with a brightly lit side and a dark side.
iHip14Δ/Δ mice spent the same amount of the time in the light box as
control mice (g; ANOVA: p = 0.58; N = 13–16). Mice were allowed
free access to a 2% sucrose solution and water over a 24-h period,
and the total fluid consumption (g/kg of body weight; h) was mea-
sured. iHip14Δ/Δ mice had no change in total fluid intake (h;
ANOVA: p = 0.27; N = 14–16) but had decreased preference for the
sucrose solution (i; ANOVA: p = 0.0066; N = 14–16)
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purposes. Post-mortem examination of 14 iHip14Δ/Δ mice
revealed signs of paralysis in 13, including splayed hind
limbs and clenched front paws. One iHip14Δ/Δ mouse
found with hind limb paralysis was monitored by video
(Additional file 1). The paralysis progressed rapidly over
5 h beginning with the hind limbs. Initially, the mouse did
not appear distressed and was able to move around the
cage and eat. Paralysis progressed until the mouse could
no longer move and it was euthanized. A second iHip14Δ/
Δ mouse was found almost completely paralyzed and was
video monitored for a few minutes until it went into re-
spiratory arrest and died (Additional file 2). These data in-
dicate that iHip14Δ/Δ mice have dramatically reduced
survival due to rapidly progressing paralysis and sudden
death.
Two iHip14Δ/Δ mice survived past 20 weeks of age
(10%). One of these mice reached a humane endpoint
due to wasting at 43 weeks of age and was euthanized.
At the time of euthanasia, it weighed 30% less than its
control littermates. The brain was harvested for bio-
chemistry to assess HIP14 protein levels to ensure
complete loss of HIP14. Indeed, negligible HIP14 protein
was detected, indicating that efficient recombination
occurred in this mouse (Fig. 7b).
Discussion
The most striking phenotype of the iHip14Δ/Δ mice is
the rapidly progressing hind limb paralysis leading to
sudden death. This was highly unexpected, as there is no
survival deficit of Hip14gt/gt mice. HIP14 is the most
highly conserved PAT, with 99% protein sequence iden-
tity between human and mouse and 88% between
human and zebrafish as well as 100% conservation of
the DHHC active site domain from human to chicken
[2]. This high sequence conservation suggests an essen-
tial function for the protein, which is supported by the
phenotype of iHip14Δ/Δ mice. The constitutive Hip14-
deficient Hip14gt/gt mouse has HD-like neurological defi-
cits [12, 20, 25]; thus, iHip14Δ/Δ mice were expected to
develop a similar phenotype. However, the severe pheno-
type of iHip14Δ/Δ mice shows that HIP14 is crucial for
the life of the adult mouse. Hip14gt/gt mice develop early
onset neurological disease, and these mice express 10%
of the endogenous levels of HIP14 in all cells [16, 17],
whereas complete loss in >90% of cells in iHip14Δ/Δ
adult mice causes a severe phenotype, including sudden
death. Thus, complete loss of HIP14 is likely not com-
patible with survival. It will be interesting to see what
happens if HIP14 is fully deleted from conception. How-
ever, there may also be developmental compensation
that occurs when HIP14 is deleted from conception,
likely by other PATs, which cannot occur when HIP14 is
deleted in the adult animal.
The iHip14Δ/Δ mice have motor coordination deficits
similar to those of Hip14gt/gt mice. The motor deficits
are dramatic, particularly in the spontaneous climbing
Fig. 5 Three-month-old iHip14Δ/Δ mice have increased brain and forebrain weight, increased cortical volume, and decreased corpus callosum
volume. iHip14Δ/Δ mice have increased brain weight compared to control mice (a; ANOVA: p = 0.0004; N = 13–18), larger forebrain weight (b;
ANOVA: p = 0.0002; N = 13–18), and unchanged cerebellum weight (c; ANOVA: p < 0.0001; N = 12–18). Brains were then sectioned and stained
with NeuN to stain neurons, and striatal (d), cortical (e), and corpus callosum (f; CC) volume were determined. No change in striatal volume was
observed (d; ANOVA: p = 0.43; N = 18–23) in iHip14Δ/Δ mice, but there was a significant increase in cortical volume (e; ANOVA: p < 0.0001; N = 13–
18) and decrease in corpus callosum volume (f; ANOVA: p < 0.0001; N = 13–18). Sections were stained with antibodies against glial fibrillary acidic
protein (GFAP) or ionized calcium-binding adapter molecule 1 (IBA1) to stain astrocytes (g and i) and microglia (h and j). There was increased
staining intensity of GFAP (g and i; ANOVA: p < 0.0001; N = 7–9) and IBA1 in iHip14Δ/Δ cortex (h and j; ANOVA: p = 0.0001; N = 7–9)
Sanders et al. BMC Biology  (2016) 14:108 Page 6 of 13
test. Also, similar to Hip14gt/gt mice [12, 25], iHip14Δ/Δ
mice have sensorimotor gating deficits. The PPI test as-
sesses the ability to inhibit an unwanted motor response
to a stimulus and is believed to be mediated by the stri-
atum [23]. Both motor dysfunction and PPI impairment
suggest striatal dysfunction in the iHip14Δ/Δ mice.
The psychiatric phenotype of the iHip14Δ/Δ mice also
suggests striatal dysfunction. The iHip14Δ/Δ mice are
hyperactive and reactive to handling, which is consistent
with the increased escape response observed during tests
of anxiety and depression. This was confirmed when
iHip14Δ/Δ mice performed similarly to control mice in the
modified light-dark box test that eliminated any avenues
for escape. However, anxiety and escape response are
likely associated. Thus, it is possible that they become
anxious when they are unable to escape a novel environ-
ment [36]. Overall, the increased escape response pheno-
type of iHip14Δ/Δ mice agrees with rodent striatal lesion
models with enhanced escape response behavior, provid-
ing further evidence of an essential role for HIP14 in stri-
atal function [37].
Interestingly, iHip14Δ/Δ mice have increased forebrain
weight due to microgliosis and astrogliosis in the cortex.
This may be a downstream response to neuron or circuit
dysfunction or may suggest a novel role for HIP14 in
glial cell function. Also, although there is clear striatal
dysfunction in iHip14Δ/Δ mice, there was no change in
striatal volume, unlike the striatal atrophy observed in
Hip14gt/gt mice [12, 38]. One possible explanation for
this discrepancy is that iHip14Δ/Δ mice die before suffi-
cient striatal neuron death for detection by stereology
has occurred. There was, however, a decrease in corpus
callosum volume, suggesting decreased white matter and
potentially axonal degeneration or demyelination.
Further evidence for striatal dysfunction was apparent
in the physiology of MSNs. Although there is no change
in membrane excitability or surface area in iHip14Δ/Δ
MSNs, they did display aberrant synaptic transmission.
The increase in sEPSC amplitude, decrease in sEPSC fre-
quency, and increased PPR suggest a lower probability
Fig. 7 Reduced survival in iHip14Δ/Δ mice and HIP14 protein
expression in the brain of a 43-week-old iHip14Δ/Δ mouse. A dramatic
reduction in survival was observed in the iHip14Δ/Δ mice compared to
controls (a; log-rank test: X2(4) = 93.76; N = 11–24). b Whole cell lysate
was run on western blot and probed with anti-HIP14 and anti-β-
tubulin antibodies. The HIP14 immunoblot is the top panel and that
of the β-tubulin is in the bottom panel. The amount of HIP14 protein
expressed is quantified in the graph relative to β-tubulin expression
(N = 3 WT VEH, 2 iHip14F/F, and 1 iHip14Δ/Δ). A 97% decrease in HIP14
was observed in the iHip14Δ/Δ mouse. The representative images are
composites from the same western blot image
Fig. 6 Impaired synaptic transmission in iHip14Δ/Δ MSNs.MSNs in the
central dorsal striatum were whole-cell patch clamped in acute coronal
slices from 3-month-old mice. A representative trace of current-clamp
membrane potential responses to a series of current injections (from –
100 pA to 200 pA in 50-pA increments) is shown in (a). iHip14Δ/Δ MSNs
had the same resting membrane potential (RMP) (b: ANOVA: p = 0.68;
N = 21–25), fired at the same rheobase current (c; ANOVA: p = 0.30; N
= 21–25), and had the same membrane capacitance (d; ANOVA:
p = 0.094; N = 31–43). iHip14Δ/Δ mice had decreased frequency
(f left; ANOVA: p < 0.0001; N = 19–23) but increased amplitude (f right;
ANOVA: p < 0.0001; N = 19–23) of spontaneous excitatory post-synaptic
currents (sEPSC), representative traces are shown in (e). iHip14Δ/Δ mice
had increased paired pulse ratios (h; PPR; two-way ANOVA: genotype
p = 0.0001; pulse interval p < 0.0001; interaction p = 0.0047; N = 8–10),
representative traces are shown in (g)
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of transmitter release but more AMPARs at excitatory
synapses in the striatum and/or more glutamate released
per synaptic vesicle to the same number of AMPARs.
Loss of palmitoylation at either palmitoylation site of
GluA1 or GluA2 AMPAR subunits would increase their
synaptic expression, which could contribute to these
phenotypes [9].
HIP14 has been shown to be a “hub” protein with
many interacting partners, and it shares many interac-
tors (not specifically substrates) with HTT, also a “hub”
protein with many interactors [39]. In addition to being
a PAT, HIP14 has also been shown to have other, non-
PAT-related, functions in MAP kinase signaling and
magnesium/manganese transport [40–42]. Thus, the
phenotype of these mice may be due to loss of palmitoy-
lation of one or multiple crucial proteins, may result
from loss of one of these other functions of HIP14, or
may be caused by a combination of all these factors.
Conclusions
This is the first study, to our knowledge, to examine the
“conditional knockout” of a DHHC PAT and conclusively
demonstrates that HIP14 is essential for life and neuronal
integrity. The iHip14Δ/Δ mice have a severe phenotype,
different than that of the Hip14gt/gt mice, that results in
sudden death, striatal dysfunction, and significant astro-
gliosis and microgliosis. These data highlight the import-
ance of this PAT to neurological function and suggest that
palmitoylation is an essential protein modification.
Methods
Generation of inducible Hip14 knockout mice
Xenogen Biosciences (now Taconic Biosciences, Rensselaer,
NY, USA) generated the Hip14 “floxed” mice (Hip14F)
on the FVB/N background strain using a gene targeting
strategy where exon 2 was selected as the conditional
deletion region, as deletion of this region leads to a
frameshift mutation and multiple premature stop co-
dons (Fig. 1a–d). The 5’ and 3’ homology arms and the
conditional knockout region (cKO) were amplified from
bacterial artificial chromosome DNA and inserted into
the targeting vector at the indicated restriction enzyme
sites such that the cKO region was flanked by loxP sites
(Fig. 1a). A positive selection neo cassette was included
and flanked by flippase (Flp) recognition target (FRT)
sites, and a negative selection cassette diphtheria toxin
A (DTA) was also included to select against random in-
sertion (Fig. 1a). Male FVB/N embryonic stem cells
were electroporated with the targeting vector and selected
using G418 (Geneticin) resistance and screened for hom-
ologous recombination at the 5′ and 3′ homology arms
with the WT allele (Fig. 1b) by restriction enzyme digest,
southern blot, and PCR. The neo cassette was then
removed in positive clones by electroporation with Flp
recombinase to mediate recombination between the FRT
sites and generate the recombined Hip14F allele (Fig. 1c).
Neo cassette deletion was confirmed by G418 sensitivity
and PCR. Hip14F embryonic stem cells were then injected
into C57BL/6 J blastocysts to generate male chimeras that
were bred with FVB/N females. Resulting white coat pro-
geny indicated germline transmission, and those mice were
genotyped using the following primers: the forward primer
in the 5′ homology arm in intron 1 (5′-GGAGAATGGT
TAGGAAAAGCTCGTACC-3′) and the reverse primer in
the cKO region in intron 1 upstream of the first loxP site
(5′-GAGGAAAGCATGCAAGAGCACTTCTC-3′).
Hip14F/F mice were then crossed to mice expressing
Cre-ERT2 under the human ubiquitin ligase C promoter, a
promoter that will result in ubiquitous Cre expression in
all cell types [18] (The Jackson Laboratory, Bar Harbor,
ME, USA). The Cre-ERT2 transgene expresses Cre recom-
binase fused to a mutated form of the estrogen receptor
that is not activated by estrogen but is activated by the
estrogen analog tamoxifen (TM) [18]. This generated
mice in which Hip14 can be deleted at any time point
(Hip14F/F;Cre-ERT2). The primers used to genotype at
the Cre-ERT2 transgene were 5′-GCGGTCTGGCAGT
AAAAACTATC-3′ and 5′- GTGAAACAGCATTGCT
GTCACTT-3′. Gene deletion was induced using a 5-
day TM treatment paradigm by giving a single intraper-
itoneal injection once a day for 5 days at a dose of
0.2 mg TM/g body weight in 98% corn oil with 2%
ethanol (iHip14F/F and iHip14Δ/Δ) or vehicle alone (WT
VEH) as previously described [18]. Mice were treated
with TM at 6 weeks of age.
Quantitative real-time PCR
Total RNA was isolated from –80 °C frozen tissues using
the RNeasy mini kit (Qiagen, Venlo, The Netherlands).
RNA was treated with DNAse I (Life Technologies, Carls-
bad, CA, USA) to remove residual genomic DNA. cDNA
was prepared from 1 μg total RNA using the SuperScript®
III First-Strand Synthesis System (Life Technologies,
Carlsbad, CA, USA). Quantitative RT-PCR (qPCR) on the
mouse Hip14 gene using primers spanning exons 1 and 2
(5′-ACCCGGAGGAAATCAAACCACAGA-3′ and 5′-T
ACATCGTAACCCGCTTCCACCAA-3′) was performed
using Power SYBR Green PCR Master Mix (Applied
Biosystems, Life Technologies, Carlsbad, CA, USA) and
the ABI 7500 Fast Real-Time PCR System (Applied Bio-
systems, Life Technologies, Carlsbad, CA, USA) under
default conditions. Each sample was run in triplicate.
Expression levels for mRNA were normalized to β-actin.
Antibodies
The primary antibodies used were HIP14 polyclonal
antibody (in house, 1:400 for immunoblotting), β-tubulin
monoclonal antibody (T8328, Sigma, RRID:AB_1844090,
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1:5000 for immunoblotting), and NeuN antibody
(MAB377, Millipore, RRID:AB_2298772, 1:1000). Biotinyl-
ated anti-mouse antibody (BA-9200, RRID:AB_2336171,
Vector Laboratories, 1:1000 for immunohistochemistry)
was used as a secondary antibody for immunohisto-
chemistry. Fluorescently conjugated secondary anti-
bodies used for immunoblotting were Alexa Fluor 680 goat
anti-rabbit (A21076, Molecular Probes, RRID:AB_2535736,
1:10000) and IRDye 800CW goat anti-mouse (610-131-121,
Rockland, RRID:AB_220123, 1: 2500).
Tissue lysis and western blotting analysis
Tissues were homogenized on ice for 5 min in one volume
1% SDS TEEN (TEEN: 50 mM Tris pH 7.5, 1 mM EDTA,
1 mM EGTA, 150 mM NaCl, and 1× complete protease
inhibitor cocktail [Roche]) and subsequently diluted in
four volumes 1% TritonX-100 TEEN for 5 min for further
homogenization. Samples were sonicated once at 20%
power for 5 s to shear DNA, and the insoluble material
was removed by centrifugation at 14,000 rpm for 15 min.
Proteins in cell lysates were heated at 70 °C in 1×
NuPAGE LDS sample buffer (Invitrogen) with 10 mM
dithiothreitol (DTT) before separation by SDS-PAGE.
After transfer of the proteins onto a nitrocellulose mem-
brane, immunoblots were blocked in 5% milk TBS (TBS:
50 mM Tris pH 7.5, 150 mM NaCl). Primary antibody
dilutions of HIP14 polyclonal antibody and β-tubulin
monoclonal antibody in 5% BSA PBST (bovine serum al-
bumin, phosphate buffered saline with 5% Tween-20)
were applied to the immunoblots at 4 °C overnight. Cor-
responding secondary antibodies were applied in 5%
BSA PBST for an hour. Fluorescence was scanned and
quantified with an Odyssey Infrared Imaging system (Li-
COR Biosciences, Lincoln, NE, USA) and quantified using
the Li-COR software. All error bars represent standard
error of the mean.
Behavior
All behavioral testing was performed with the tester blind
to genotype. All testing was performed at 3 months of age
(7 weeks post-TM injection). All of the apparatuses were
cleaned between mice with 70% ethanol.
Spontaneous activity
Spontaneous activity in the dark was measured using
the Med Associates activity monitoring system (Med
Associates Inc., St Albans, VT, USA) as previously de-
scribed [20]. Briefly, no later than 1 h after the begin-
ning of the dark cycle following 1 h of acclimatization
to the room, mice were placed in the center of the test-
ing chamber (27 × 27 × 20.3 cm) and allowed to freely
move about and explore for half an hour. A number of
automated readouts were recorded. Ambulatory time is
the total time the mouse spent moving while making
consecutive beam breaks and ambulatory episodes are
the number of times the mouse began ambulating from
a resting position.
Rotarod and climbing
Fixed-speed and accelerating rotarods were used to assess
motor coordination (Ugo Basile, Comerio, Italy) as previ-
ously described [20]. Briefly, mice were trained once a day
for 3 days on the fixed-speed 18-rpm rotarod for 120 s,
and the number of falls and latency to the first fall were
recorded. On the fourth day, mice were tested on an ac-
celerating rotarod that accelerates from 5 to 40 rpm over
300 s, and the latency to fall was recorded. The average of
three trials is reported.
Motor coordination was also tested on the climbing
apparatus as previously described [21]. Briefly, mice
were placed inside a closed-top wire mesh cylinder
(10 × 15 cm) on the tabletop and were allowed to freely
explore for 300 s while being video recorded. A climb-
ing event was recorded when all four paws were off the
surface of the tabletop and a rearing event was re-
corded when the forepaws were off the surface of the
tabletop. The climbing time was recorded as the total
time from when the fourth paw left the tabletop to
when the first paw touched back down.
Pre-pulse inhibition (PPI)
PPI was performed using the Startle Response System
(San Diego Instruments, San Diego, CA, USA) as previ-
ously described [25]. Briefly, mice were placed in a star-
tle chamber and allowed to acclimatize with background
noise for 5 min. Mice were then exposed to six trials of
a 40-ms, 120-dB startle pulse to test the acoustic startle
response. Mice were then exposed to eight blocks of six
(48 trials in total) pseudorandomized trials of (1) no
stimulus, (2) the 40-ms, 120-dB startle pulse alone, or
(3–6) the 40-ms, 120-dB startle pulse preceded 100 ms
by a 20-ms pre-pulse of 2, 4, 8, or 16 dB above back-
ground. An extra 40-ms, 120-dB pulse was given in four
of the eight blocks. Finally, the mice were exposed to an-
other six trials of the 40-ms, 120-dB startle pulse. The
inter-trial interval was between 8 and 23 s and was pseu-
dorandomized between trials. PPI is the percentage of
decrease in the startle response when a pre-pulse is
given prior to the startle pulse and was calculated as the
average of six trials per pre-pulse as follows: PPI = [(startle
pulse-alone startle) - (pre-pulse + startle pulse startle)]/
pulse-alone startle.
Porsolt forced swim test
The Porsolt forced swim test was used to assess
depressive-like behavior and was performed as previ-
ously described [26–28, 43]. Briefly, mice were placed in
individual cylinders (25 cm tall × 19 cm wide) filled with
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room temperature water to a depth of 15 cm and
allowed to swim for 6 min while being recorded by video
camera. The time spent immobile (not swimming) dur-
ing the final 5 min was scored.
Open field
Open field exploration was used as a test of anxiety-like
behaviors as previously described [21]. Briefly, mice were
placed into the lower left corner of a 50 × 50 cm open gray
Plexiglas box with 16-cm sides in a brightly lit room. The
mice were allowed to explore the box for 10 min while be-
ing recorded via ceiling-mounted video camera. Videos
were live scored using Ethovision XT 7 animal tracking
software (Noldus Information Technology), and the total
distance traveled and the total time spent in the center of
the field were scored as measures of exploratory activity
and anxiety-like behavior, respectively.
Elevated plus maze
EPM exploration was used as a test of anxiety-like behav-
ior as previously described [31]. Briefly, mice were
placed in the center of an EPM 50 cm off the ground
with 30 × 10 cm arms, two of which are enclosed by 20-
cm walls. Mice were allowed to freely explore the maze
for 5 min while a ceiling-mounted camera recorded
their activity and Ethovision XT 7 live scored the videos.
Distance traveled was used to assess exploratory activity.
The time spent in the open arms (open arm duration) and
head dips off the edges of the open arms were used as
measures of anxiety-like behavior.
Light-dark box
The light-dark box was used to test for anxiety in an
environment where escape was not possible, i.e., a com-
pletely enclosed environment. The Gemini Avoidance
System (San Diego Instruments) was used for this pur-
pose; no cues or shocks were used. The door between
the two chambers was kept open so mice could freely
explore both sides of the box, and on one side a light
was shone through the transparent door to create a
brightly lit light box. The door on the other side was
blacked out to create a dark box. Mice were allowed to
freely explore the apparatus, and their activity was re-
corded using a video camera through the light box side.
The total time spent in the light box was scored as a
measure of anxiety-like behavior.
Sucrose preference
Sucrose preference was used to test for anhedonia, or
the loss of pleasure-seeking behaviors, a symptom of de-
pression, as previously described [26, 44]. Briefly, mice
were single housed in a full-size cage and were given ad
libitum access to food and to two water bottles. Mice
were allowed to acclimatize to the bottles for 1 week.
On day 7 the water in one of the bottles was replaced with
a 2% sucrose solution and the mice and both bottles were
weighed. Twenty-four hours later the bottles were
weighed again and the total fluid and sucrose intake were
calculated as g/kg of body weight. Sucrose preference was
calculated as follows: sucrose preference = (sucrose intake/
total fluid intake) × 100.
Neuropathology
All neuropathological studies were conducted as previ-
ously described [12, 31]. Mice were anesthetized by in-
traperitoneal injection of 2.5% avertin and intracardially
perfused with ice-cold 4% paraformaldehyde. Brains
were harvested and post-fixed in 4% paraformaldehyde
for 24 h at 4 °C, and then cryopreserved in 30% sucrose
in phosphate-buffered saline (PBS). To determine the
brain weight, the olfactory bulbs, paraflocculi, and brain
stem were removed prior to weighing. The cerebellum
was then removed and weighed separately. Forebrain
weight was calculated as brain weight minus cerebellum
weight. The forebrain was then flash frozen on dry ice,
mounted with Tissue-TEK O.C.T. compound (Sakura
Finetek, Torrance, CA, USA), and sectioned coronally
on a cryostat (Microm HM 500 M) into 25-μm free-
floating sections. Sections were stored until immunohisto-
chemical processing in PBS with 0.01% sodium azide.
A series of 25-μm sections spaced 200 μm apart span-
ning the striatum were processed for stereological volumet-
ric assessments by staining with NeuN antibody (1:1000,
Millipore MAB377) overnight at room temperature to
stain all neuronal nuclei. Sections were then stained with
biotinylated anti-mouse antibody for 2 h (1:1000, Vector
Laboratories BA-9200) and the signal was amplified using
the Vectastain ABC kit for 30 min (1:1000, Vector Labora-
tories) and then detected with 3,3′-diaminobenzidine
(DAB, Thermo Scientific). StereoInvestigator software
(Microbrightfield Bioscience, Williston, VT, USA) was used
to determine striatal, cortical, and corpus callosum vol-
umes by tracing the perimeter of the desired structures;
the volumes were determined using the Cavalieri principle.
Two additional series of sections described above were
used for glial fibrillary acidic protein (GFAP) and ionized
calcium-binding adapter molecule 1 (IBA1) immunohis-
tology. Sections were blocked with 3% H2O2 in PBS for
30 min, then washed with PBS. Sections were then
blocked with 5% normal goat serum (NGS) in PBS-Triton
for 30 min. Sections were incubated overnight at room
temperature in either monoclonal mouse anti-GFAP-Cy3
antibody (1:500, Sigma-Aldrich) or polyclonal rabbit anti-
IBA1 antibody (1:500, Wako), both solutions made in 1%
NGS and PBS-Triton. Sections were then incubated for
2 h at room temperature in either biotinylated goat anti-
mouse IgG antibody (1:500, Vector) or biotinylated goat
anti-rabbit IgG antibody (1:500, Vector), both solutions
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made in 1% NGS and PBS-Triton. Lastly, sections were
incubated with the Vectastain ABC kit (1:1000, Vector)
for 30 min and developed with DAB (1:10, Sigma-Aldrich)
for 2 min. Sections were mounted on Superfrost Plus
microscope slides (Fisher) prior to analysis. Sections were
imaged on a Zeiss Axioplan 2 imaging system with a 5×
Zeiss Plan-Neofluar objective using a Photometrics Cool
Snap HQ camera. Analyses were done using MetaMorph
software version 6.3 (Universal Imaging Corporation,
Bedford Hills, NY). After delineating the cortex for each
image, labeling of GFAP and IBA1 was identified using
the threshold held at a constant level with background ex-
cluded for all images and then analyzed using the “inte-
grated morphometry” feature. Relative levels of GFAP and
IBA1 staining were calculated as the sum of the integrated
optical density (IOD) for each image divided by the area
of the region selected, then multiplied by the sampling
interval (8) and section thickness (25 μm). No staining
was observed in a negative control without primary anti-
body [31].
Electrophysiology
Mice were transferred to the University of British
Columbia (UBC) Animal Research Unit approximately
4–5 weeks following TM injections and all electro-
physiological experiments were performed on mice that
were approximately 3 months old. Electrophysiological
analyses were performed as previously described [14].
Briefly, mice were anesthetized with isoflurane and
brains were quickly removed and immediately placed in
an ice-cold cutting solution that contained (in milli-
moles): 125 NaCl, 2.5 KCl, 25 NaHCO3, 1.25 NaH2PO4,
2.5 MgCl2, 0.5 CaCl2, and 10 glucose. Coronal blocks
containing the striatum were then cut on a vibratome
(Leica VT1200S) at 400 μm. Striatal sections were trans-
ferred to artificial cerebrospinal fluid (ACSF), which was
the same as the cutting solution except that it contained
1 mM MgCl2 and 2 mM CaCl2, and were heated to
approximately 32 °C for 30–45 min.
Following recovery, slices were transferred to a record-
ing chamber with ACSF perfused at a rate of 2–3 ml/min.
In striatal sections, spiny projection neurons in the dorsal
striatum were targeted for recording [14]. For excitatory
post-synaptic current (EPSC) recordings in the striatum,
picrotoxin (50 μM) was added to the ACSF, but tetrodo-
toxin (TTX, 0.5 mM) was omitted, as we have previously
shown that most EPSCs in our coronal slice preparation
are action potential-independent [45]. However, while
largely action potential-independent, these are referred to
as spontaneous EPSCs (sEPSCs) in the manuscript to indi-
cate the lack of TTX. Glass pipettes (3–6 MΩ) were filled
with a potassium gluconate (KGlu) internal solution for
sEPSC recordings [46]. The liquid junction potential (the-
oretical = –15.6 mV) was left uncorrected. sEPSCs were
filtered at 1 kHz and digitized at 20 kHz. Where applic-
able, glutamate release was evoked by an ACSF-filled
glass pipette (1 MΩ) placed 200–250 μm dorsal to the
recorded cell. Paired pulse ratios (PPRs) were obtained
at a –70 mV holding voltage, and various inter-pulse
intervals were applied with a stimulus intensity known
to generate a response approximately 30–40% of the
maximal response. Basic membrane properties were ob-
tained within 60 s following break-in by monitoring the
current response to a 10-mV voltage step applied in the
membrane test feature in Clampex 10 (Molecular Devices,
Sunnyvale, CA, USA). All electrophysiological recordings
were acquired and analyzed using the pClamp 10 software
bundle.
Statistics
Data were analyzed using the Student’s t test, one-way
ANOVA, or two-way ANOVA as indicated using Prism 5
software where all post hoc tests in ANOVA analyses used
Bonferroni’s multiple comparison test. Error bars indicate
standard error of the mean and in all graphs the mean is
indicated. * p < 0.05, ** p < 0.01, *** p < 0.001. In all cases,
except for Fig. 6, the number of replicates (N) refers to the
number of individual mice used and is considered to mean
biological replicates. In Fig. 6, N refers to the number of
cells analyzed from a total of 4 mice per genotype.
ANOVA values and exact numbers are listed in Additional
file 3.
Additional files
Additional file 1: Rapidly progressing paralysis in an iHip14Δ/Δ mouse
over the course of 5 h. An iHip14Δ/Δ mouse found with hind limb
paralysis was monitored by video. The paralysis progressed rapidly over
5 h, beginning with the hind limbs, from where the mouse was able to
move around the cage and eat until it could no longer move and was
euthanized. The video lasts a total of 7 min, with the first minute from
the beginning of the 5 h and the rest of the video just before the mouse
was euthanized. (MOV 12680 kb)
Additional file 2: Sudden death due to rapidly progressive paralysis in
an iHip14Δ/Δ mouse. A second iHip14Δ/Δ mouse was found almost
completely paralyzed and was video monitored for a few minutes until it
went into respiratory arrest and died. (MOV 6931 kb)
Additional file 3: One-way and two-way ANOVA values and replicates.
(XLSX 40 kb)
Additional file 4 Individual data values for experiments where N < 6.
(XLSX 44 kb)
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